10.11.2016
Evotec AG DE0005664809
DGAP-News: EVOTEC AND OXFORD CREATE NOVEL PARTNERSHIP CALLED 'LAB282'
DGAP-News: Evotec AG / Key word(s): Alliance
EVOTEC AND OXFORD CREATE NOVEL PARTNERSHIP CALLED 'LAB282'
10.11.2016 / 07:15
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- LAB282 is a joint effort by Oxford University, Oxford University
Innovation Ltd, Oxford Sciences Innovation and Evotec to select and
accelerate early-stage projects out of Oxford University with ₤ 13 m (over
EUR 14 m) translational discovery fund
Hamburg, Germany, 10 November 2016:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced a novel strategic partnership with the University of Oxford,
Oxford University Innovation Ltd, OUI (the university's research
commercialisation company) and Oxford Sciences Innovation, OSI (the world's
largest IP investment company dedicated to a single university) aimed at
accelerating the translation of basic biomedical research from Oxford into
new therapeutics. Projects will be sourced exclusively from Oxford
University researchers via OUI across any therapeutic area and for any
therapeutic modality and will be aided by a drug discovery expert in
residence seconded by Evotec to the LAB282 initiative and embedded in the
university.
"LAB282" will be supported by a fund of ₤ 13 m (over EUR 14 m) led by OSI
for an initial period of three years. The goal is to accelerate the
achievement of pre-clinical proof of concept for new drugs and to generate
new spin-out companies. The development of new treatments and cures for
serious and debilitating diseases will help patients live longer and better
lives as well as reduce the burden on global healthcare systems.
Evotec will exclusively contribute its drug discovery expertise and
platforms to select projects and develop them further. Evotec will be
entitled to equity in new LAB282 spin-out companies together with Oxford
University and its academic researchers and together with OSI will have the
right to co-invest in seed financing rounds.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "LAB282 is
a highly innovative partnership that elegantly combines core strengths of
academia, biotech, venture capital and strong links to Pharma under one
"roof". Casting a wide net in terms of indications and technologies, it is
designed to accelerate in particular first-in-class and potentially
disruptive early-stage projects to value inflection points that will
facilitate the formation of companies. We are very proud to be part of this
exciting endeavour with such highly distinguished partners and are
convinced that this model will become a blueprint of effectively and
efficiently translating academic science into highly differentiated product
opportunities."
Dr Adam Stoten, Head of Technology Transfer, Life Sciences at OUI
commented: "This pioneering approach addresses a major unmet need by
engaging LAB282's partners, together offering world-class medical research,
commercial drug discovery expertise and facilities, and significant
investment resources. Today's announcement provides another great example
of how UK universities are at the forefront of collaborative public-private
drug discovery partnerships with the goal of patient benefit."
Professor Matthew Wood, Associate Head of Medical Sciences Division
(Research) at Oxford University, said: "LAB282 represents an important
innovation for Oxford in maximising the impact of public funding in medical
sciences. As the number one ranked medical school in the world it is
critically important that the quality of our research is matched by
high-quality translational support which increases the likelihood of future
societal benefits."
Andrew McLean, Principal Investor, OSI added: "There are so many incredible
and potentially life-changing ideas being fostered across Oxford University
and we are delighted to be part of this unique partnership to nourish these
ideas into leading companies that will have a positive impact on patients."
ABOUT LAB282
LAB282, initiated in November 2016, is a new £ 13 m partnership between the
University of Oxford, Oxford University Innovation Ltd, Oxford Sciences
Innovation plc and Evotec AG created to identify and develop new approaches
to treating serious diseases which originate from the University of Oxford.
The name is derived from the pantone colour code of "Oxford Blue". For more
information, please visit www.lab282.org.
ABOUT OXFORD UNIVERSITY'S MEDICAL SCIENCES DIVISION
The Division is one of the largest biomedical research centres in Europe,
with over 2,500 people involved in research and more than 2,800 students.
The University is rated the best in the world for medicine, and it is home
to the UK's top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in
neuroscience, Oxford is at the forefront of medical research. It has one of
the largest clinical trial portfolios in the UK and great expertise in
taking discoveries from the lab into the clinic. Partnerships with the
local NHS Trusts enable patients to benefit from close links between
medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of
clinical research units in Asia and Africa, enabling world-leading research
on the most pressing global health challenges such as malaria, TB, HIV/AIDS
and flu. Oxford is also renowned for its large-scale studies which examine
the role of factors such as smoking, alcohol and diet on cancer, heart
disease and other conditions.
ABOUT OXFORD SCIENCES INNOVATION
Oxford Sciences Innovation plc is the world's largest IP investment company
dedicated to a single university. Founded in May 2015, we help turn Oxford
University's world-leading scientific discovery into innovative science and
technology companies that can have a positive impact on society.
We provide capital and expertise to businesses driven by intellectual
property developed in Oxford's Mathematical, Physical, Life Sciences
Division and Medical Sciences Divisions. We are guided and powered by some
of the world's leading organisations, including Invesco, Woodford
Investment Management, the Wellcome Trust and Lansdowne Partners.
ABOUT OXFORD UNIVERSITY INNOVATION
Oxford University Innovation supports innovation activities across all
University Divisions, managing technology transfer and consulting
activities, and providing an innovation management service to clients
around the world.
We provide access to technology from Oxford researchers through
intellectual property licensing, spinout company formation and material
sales, and to academic expertise through our Consulting Services team. The
New Venture Support & Funding team supports investors or donors with an
interest in early-stage ventures, and manages the Oxford Angels Network.
Our Startup Incubator supports members and ex-members of the University who
wish to start or grow entrepreneur-driven ventures that are not University
spinouts.
Oxford University Innovation is the highest university patent filer in the
UK and is ranked 1st in the UK for university spin-outs, having created
over 140 new companies in 25 years. In the last reported financial year we
completed 529 licenses and consulting agreements. Isis Enterprise, our
innovation management consultancy, works with university, government and
industrial clients from offices around the world.
For updates on innovations from Oxford, follow Oxford University Innovation
on LinkedIn and Twitter or subscribe at
http://innovation.ox.ac.uk/about/contact-us.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer
in the field of tissue fibrosis. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
MEDIA CONTACTS
Oxford University
Chris McIntyre, Media Relations Manager
[email protected]
T: +44 (0)1865 270 046
Oxford Sciences Innovation
Christian Seiersen, Milltown Partners
[email protected]
T: +44 (0)20 7487 2583
Oxford University Innovation
Simon Gray, Head of Marketing
[email protected]
T: +44 1865 614 428
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
10.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
519223 10.11.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT